SLC5A2 and hydrops fetalis: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been shown to reduce HF hospitalizations and cardiovascular death across all ranges of LVEF, and there is now a class I indication for SGLT2 inhibitors in HFrEF and a class IIa indication for HFpEF (46).